A Study on Evaluation of Drug-Drug Interactions in Cardiovascular Disease Patients in a Tertiary Care Hospital
Abstract
Cardiovascular disease remains a major cause of premature mortality and rising health care costs. Cardio metabolic, behavioral, environmental, and social risk factors are major drivers of cardiovascular disease. The present study aimed to assess drug-drug interactions in cardiovascular disease patients in a tertiary care hospital. 36-46 years age patients were more 59 (34.70%) as compared to 47-56 years age patients were 44 (25.88%), 57-67 years age patients were 42 (24.70%). Moderate drug-drug interaction patients were more 81 (47.64%) as compared to other drug interactions. Aspirin + Clopidogrel drugs drug interactions were more 74 (43.52%) as compared to other drug interactions. The study found that incidence of drug interactions was associated with old age, polypharmacy and increased lengths of hospital stay. The development of such data base in hospitals may help for the surveillance of drug interactions in hospitalized cardiac patients. Patients with cardiovascular disorders are subjected to high risk of potential drug-drug interactions and the number of drugs prescribed and educational level of the prescribers has a high significantly associated with the occurrence of potential drug-drug interactions.
Keywords:
Cardiovascular disease, Polypharmacy, Hospitalized cardiac patients, Drug interactions, Hospital stayDOI
https://doi.org/10.70604/learnint.v2i1.58References
1. Pagidipati N.J., Gaziano T.A. Estimating Deaths from Cardiovascular Disease: A Review of Global Methodologies of Mortality Measurement. Circulation. 2013;127:749–756. doi: 10.1161/CIRCULATIONAHA.112.128413. [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Wong N.D., Budoff M.J., Ferdinand K., Graham I.M., Michos E.D., Reddy T., Shapiro M.D., Toth P.P. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. Am. J. Prev. Cardiol. 2022;10:100335. doi: 10.1016/j.ajpc.2022.100335. [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Sonja F., Nola I.A. Management of Measurable Variable Cardiovascular Disease’ Risk Factors. Curr. Cardiol. Rev. 2018;14:153–163. doi: 10.2174/1573403X14666180222102312. [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Amini M., Zayeri F., Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: Results from global burden of disease study 2017. BMC Public Health. 2021;21:401. doi: 10.1186/s12889-021-10429-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Sanz M., Del Castillo A.M., Jepsen S., Juanatey J.R.G., D’Aiuto F., Bouchard P., Chapple I., Dietrich T., Gotsman I., Graziani F., et al. Periodontitis and cardiovascular diseases: Consensus report. J. Clin. Periodontol. 2020;47:268–288. doi: 10.1111/jcpe.13189. [DOI] [PMC free article] [PubMed] [Google Scholar]
6. Cheung A.K., Sarnak M.J., Yan G., Dwyer J.T., Heyka R.J., Rocco M.V., Teehan B.P., Levey A.S. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353–362. doi: 10.1046/j.1523-1755.2000.00173.x. [DOI] [PubMed] [Google Scholar]
7. Mahmoud R., Setorki M., Doudi M., Baradaran A., Nasri H. Atherosclerosis: Process, Indicators, Risk Factors and New Hopes. Int. J. Prev. Med. 2014;5:927–946. [PMC free article] [PubMed] [Google Scholar]
8. Mitchell G.F., Powell J.T. Arteriosclerosis. Arter. Thromb. Vasc. Biol. 2020;40:1025–1027. doi: 10.1161/ATVBAHA.120.314208. [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Helvaci M.R., Tonyali O., Abyad A. The Safest Value of Plasma Triglycerides. World Fam. Med. J./Middle East J. Fam. Med. 2019;17:22–27. doi: 10.5742/MEWFM.2019.93662. [DOI] [Google Scholar]
10. Shao C., Wang J., Tian J., Tang Y.-D. Coronary Artery Disease: Therapeutics and Drug Discovery. Volume 1177. Springer; Singapore: 2020. Coronary Artery Disease: From Mechanism to Clinical Practice; pp. 1–36. Advances in Experimental Medicine and Biology. [DOI] [PubMed] [Google Scholar]
11. Badimon L., Padró T., Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care. 2012;1:60–74. doi: 10.1177/2048872612441582. [DOI] [PMC free article] [PubMed] [Google Scholar]
12. 12.Zannad F., Bauersachs R. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection? Thromb. Haemost. 2018;118:S12–S22. doi: 10.1055/s-0038-1636530. [DOI] [PubMed] [Google Scholar]
13. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–325. doi: 10.1038/nature10146. [DOI] [PubMed] [Google Scholar]
14. Brouwers S., Sudano I., Kokubo Y., Sulaica E.M. Arterial hypertension. Lancet. 2021;398:249–261. doi: 10.1016/S0140-6736(21)00221-X. [DOI] [PubMed] [Google Scholar]
15. Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D., Ramirez A., Schlaich M., Stergiou G.S., Tomaszewski M., et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. [DOI] [PubMed] [Google Scholar]
16. Wang X., Khalil R.A. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv. Pharmacol. 2018;81:241–330. doi: 10.1016/bs.apha.2017.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
17. Kopp W. How Western Diet and Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases. Diabetes Metab. Syndr. Obes. Targets Ther. 2019;12:2221–2236. doi: 10.2147/DMSO.S216791. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Medina-Leyte D., Zepeda-García O., Domínguez-Pérez M., González-Garrido A., Villarreal-Molina T., Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci. 2021;22:3850. doi: 10.3390/ijms22083850. [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Gimbrone M.A., Jr., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res. 2016;118:620–636. doi: 10.1161/CIRCRESAHA.115.306301. [DOI] [PMC free article] [PubMed] [Google Scholar]
20. VanderLaan P., Reardon C.A., Getz G.S. Site Specificity of Atherosclerosis: Site-Selective Responses to Atherosclerotic Modulators. Arter. Thromb. Vasc. Biol. 2004;24:12–22. doi: 10.1161/01.ATV.0000105054.43931.f0. [DOI] [PubMed] [Google Scholar]
21. Mussbacher M., Schossleitner K., Kral-Pointner J.B., Salzmann M., Schrammel A., Schmid J.A. More than Just a Monolayer: The Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis. Curr. Atheroscler. Rep. 2022;24:483–492. doi: 10.1007/s11883-022-01023-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Michiels C. Endothelial cell functions. J. Cell. Physiol. 2003;196:430–443. doi: 10.1002/jcp.10333. [DOI] [PubMed] [Google Scholar]
23. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 2007;115:1285–1295. doi: 10.1161/CIRCULATIONAHA.106.652859. [DOI] [PubMed] [Google Scholar]
24. Gutiérrez E., Flammer A.J., Lerman L.O., Elízaga J., Lerman A., Fernández-Avilés F. Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 2013;34:3175–3181. doi: 10.1093/eurheartj/eht351. [DOI] [PMC free article] [PubMed] [Google Scholar]
25. Bäck M., Yurdagul A., Jr., Tabas I., Öörni K., Kovanen P.T. Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities. Nat. Rev. Cardiol. 2019;16:389–406. doi: 10.1038/s41569-019-0169-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Xia Z., Gu M., Jia X., Wang X., Wu C., Guo J., Zhang L., Du Y., Wang J. Integrated DNA methylation and gene expression analysis identifies SLAMF7 as a key regulator of atherosclerosis. Aging. 2018;10:1324–1337. doi: 10.18632/aging.101470. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Marchio P., Guerra-Ojeda S., Vila J.M., Aldasoro M., Victor V.M., Mauricio M.D. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid. Med. Cell Longev. 2019;2019:8563845. doi: 10.1155/2019/8563845. [DOI] [PMC free article] [PubMed] [Google Scholar]
28. 28.Wolf D., Ley K. Immunity and Inflammation in Atherosclerosis. Circ. Res. 2019;124:315–327. doi: 10.1161/CIRCRESAHA.118.313591. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Du W., Xu A., Huang Y., Cao J., Zhu H., Yang B., Shao X., He Q., Ying M. The role of autophagy in targeted therapy for acute myeloid leukemia. Autophagy. 2021;17:2665–2679. doi: 10.1080/15548627.2020.1822628. [DOI] [PMC free article] [PubMed] [Google Scholar]
30. Jaiswal S., Natarajan P., Silver A.J., Gibson C.J., Bick A.G., Shvartz E., McConkey M., Gupta N., Gabriel S., Ardissino D., et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N. Engl. J. Med. 2017;377:111–121. doi: 10.1056/NEJMoa1701719. [DOI] [PMC free article] [PubMed] [Google Scholar]
Published
Abstract Display: 34 
PDF Downloads: 13 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/lapinjournals/domains/lapinjournals.com/public_html/plugins/generic/citations/CitationsPlugin.php on line 68
.